IncyteINCY
INCY
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
116% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 58
86% more call options, than puts
Call options by funds: $68.6M | Put options by funds: $37M
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
14% more repeat investments, than reductions
Existing positions increased: 236 | Existing positions reduced: 207
10% more funds holding
Funds holding: 577 [Q3] → 633 (+56) [Q4]
6% more capital invested
Capital invested by funds: $11.9B [Q3] → $12.6B (+$659M) [Q4]
0.01% more ownership
Funds ownership: 94.74% [Q3] → 94.75% (+0.01%) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$65
7%
upside
Avg. target
$76
25%
upside
High target
$92
51%
upside
7 analyst ratings
1 positive
14%
6 neutral
86%
0 negative
0%
Morgan Stanley Vikram Purohit 29% 1-year accuracy 2 / 7 met price target | 7%upside $65 | Equal-Weight Maintained | 24 Mar 2025 |
Truist Securities Srikripa Devarakonda 36% 1-year accuracy 12 / 33 met price target | 18%upside $72 | Hold Maintained | 18 Mar 2025 |
Guggenheim Michael Schmidt 29% 1-year accuracy 10 / 35 met price target | 51%upside $92 | Neutral Downgraded | 18 Mar 2025 |
RBC Capital Brian Abrahams 20% 1-year accuracy 14 / 70 met price target | 12%upside $68 | Sector Perform Maintained | 11 Feb 2025 |
Citigroup David Lebowitz 32% 1-year accuracy 6 / 19 met price target | 44%upside $88 | Buy Maintained | 11 Feb 2025 |
Financial journalist opinion
Based on 19 articles about INCY published over the past 30 days
Negative
Market Watch
23 hours ago
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Neutral
GlobeNewsWire
6 days ago
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V.
Neutral
The Motley Fool
1 week ago
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.
Negative
Zacks Investment Research
2 weeks ago
INCY Stock Down on Disappointing Skin Disease Study Data
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
Positive
Seeking Alpha
2 weeks ago
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is expected to be worth $1.57 billion by 2031; Incyte can do well in biologic experienced HS patients. Regulatory discussions possible of expanded approval of OPZELURA for Prurigo Nodularis patients; However, regulatory discussion will be needed to determine if one phase 3 study will be enough for filing.
Neutral
Investopedia
2 weeks ago
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Negative
Barrons
2 weeks ago
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Negative
Schaeffers Research
2 weeks ago
Incyte Stock Eyes Worst Day Since 2018 After Trial Results
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
Positive
Benzinga
2 weeks ago
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Negative
Investors Business Daily
2 weeks ago
Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed. The post Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' appeared first on Investor's Business Daily.
Charts implemented using Lightweight Charts™